BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution |
| |
Authors: | Kamila Sroka&dagger ,Aaron Voigt&dagger &Dagger ,Sebastian Deeg&dagger ,John C. Reed§ ,Jö rg B. Schulz&dagger &Dagger ,Mathias Bä hr&dagger , Pawel Kermer&dagger |
| |
Affiliation: | Department of Neurology, University Hospital Göttingen, Waldweg, Göttingen, Germany; DFG Research Center for Molecular Physiology of the Brain (CMPB), Göttingen, Germany; Department of Neurodegeneration and Restorative Research, Center of Neurological Medicine, University Hospital Göttingen, Waldweg, Göttingen, Germany; Burnham Institute for Medical Research, La Jolla, California, USA |
| |
Abstract: | Bcl-2-associated athanogene-1 (BAG1) is a multifunctional protein delivering chaperone-recognized unfolded substrates to the proteasome for degradation. It has been shown to be essential for proper CNS development in vivo, playing a crucial role in neuronal survival and differentiation. With regard to Huntington's disease, a sequestration of BAG1 into inclusion bodies and a neuroprotective effect in double transgenic mice have been reported. Here, we show that BAG1 reduces aggregation and accelerates degradation of mutant huntingtin (htt-mut). Moreover, it reduces nuclear levels of htt-mut. This effect can be overcome by over-expression of seven in absentia homolog 1, an E3 ligase negatively regulated by BAG1 and known to be involved in nuclear import of htt-mut. In vivo , BAG1 proved to be protective in a Drosophila melanogaster Huntington's disease model, preventing photoreceptor cell loss induced by htt-mut. In summary, we present BAG1 as a therapeutic tool modulating key steps in htt toxicity in vitro and ameliorating htt toxicity in vivo . |
| |
Keywords: | aggregation Bcl-2-associated athanogene-1 Huntington's disease proteasomal degradation polyglutamine seven in absentia homolog 1 |
|
|